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Epidemiological study of multiple
sclerosis in Hong Kong Chinese:
questionnaire survey
Objective. To study the epidemiology of multiple sclerosis in Hong Kong
Chinese.
Design. Cross-sectional questionnaire survey.
Setting. Neurology and paediatric neurology departments in Hong Kong from
January through June 1999.
Participants. All confirmed multiple sclerosis patients.
Main outcome measures. Demographic data, investigation results, Kurtzke’s
Expanded Disability Status Scale during the last follow-up visit, number of
relapses between 1997 and 1998, and treatments used/currently in use.
Results. Fifty-three Chinese multiple sclerosis patients were identified. The
prevalence was thus estimated to be 0.77 per 100 000 population. This low
prevalence was also noted in other multiple sclerosis studies from South-East
Asia (range, 0.8-4 per 100 000 population). The female to male ratio among the
Chinese multiple sclerosis sufferers was 9.6:1, a figure somewhat higher than
that reported in the other studies from South-East Asia (range, 3.2-6.6:1). The
Chinese multiple sclerosis patients in this study also had a high spinal cord
involvement (66%) and a low presence of cerebrospinal fluid oligoclonal
banding (40%). These findings were different from those in Caucasian multiple
sclerosis patients.
Conclusion. Multiple sclerosis in Hong Kong Chinese has a low prevalence, a
high female to male ratio, and a low cerebrospinal fluid oligoclonal banding
presence.
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Introduction
Multiple sclerosis (MS) is a particularly devastating disease of the central nervous
system (CNS), as it strikes predominantly young adults during their most
productive years. Even when patients are asymptomatic, they cannot predict when
their condition will relapse again. The use of interferon and other immunomodu-
lating therapies has been shown to be effective in the treatment of MS. For
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example, studies have clearly shown that patients on inter-
feron treatment have significantly longer mean symptom-
free periods, shorter hospitalisation stays, and less burden
of disease according to magnetic resonance imaging (MRI)
brain scans.1-4 However, these trials involved Caucasian MS
sufferers, and to date there have been no controlled trials of
interferon treatment in Chinese MS sufferers. Although it is
tempting to assume that Chinese MS patients will respond
to interferon treatment in the same way as their Caucasian
counterparts, a study in Japan has shown that not only do
Asians have a lower prevalence of the disease, but also a
different pattern, suggesting heterogeneity in the immuno-
genetic background.5 Accordingly, this survey was designed
to study the prevalence of MS in Hong Kong Chinese and
to characterise the clinical features of the disease.
Methods
Between January and June 1999, a territory-wide, cross-
sectional survey of MS patients in Hong Kong was carried
out among all neurologists and some paediatric neurologists
who look after paediatric MS patients. Questionnaires
concerning patients’ demographic and clinical characteristics
were compiled. Investigation results including computed
tomography (CT), MRI, evoked potential studies, and lum-
bar puncture studies (cerebrospinal fluid [CSF] oligoclonal
banding) were also documented. Patients’ clinical status, ie
degree of neurological impairment, were assessed using
Kurtzke’s Expanded Disability Status Scale (EDSS).6
The number of relapses patients experienced over a 2-year
period (1997-1998) were recorded, as were their past and
present treatment.
In some hospitals where there was no neurologist, the
questionnaires were sent to physicians with an interest in
neurology. To ensure that they were fully completed, the
questionnaires were followed-up by telephone. Hospital
visits and reviews of case notes were carried out on demand
to confirm the diagnosis and current status of MS sufferers.
Patients remained anonymous throughout the data
collection process, thereby protecting their privacy, and only
those who had been followed-up in the 2 years prior to the
study (ie 1997-1998) were included in the survey.
Results
Fifty-three Chinese MS patients were identified, of whom 48
were women and five were men. Fifty-one patients already
had their diagnoses established by neurologists, while the
two remaining MS sufferers had their diagnoses confirmed
after neurologists had the opportunity to review their
hospital records. Two non-Chinese (Caucasian) MS patients
were also identified, but were not recruited to this survey.
The patients’ demographic and clinical characteristics
(Tables 1 and 2), evoked potential and CSF oligoclonal
banding results (Table 3), and use of immunomodulating
therapies (Table 4), are summarised. Two patients had a
family history of the disease. For each patient, the clinical
course of the disease was classified according to the
criteria suggested by Poser et al7: relapsing-remitting type;
secondary progressive type; primary progressive type; or
progressive relapsing type.
Investigations
Fifty-two of the 53 patients had MRI and/or CT scans of
the brain/spinal cord. Of these, 46 (ie 88% of the total
number of patients and 87% of the number with scans) had
Table 1. Demographic characteristics of Chinese multiple
sclerosis patients in Hong Kong
Demographic characteristic
Female:male 9.6:1
Age of onset of symptoms (years) 29.4 (range, 11-60)
Age of diagnosis (years) 32.8 (range, 13-64)
Table 2. Clinical characteristics of Chinese multiple sclerosis
patients in Hong Kong
Patients, n=53
No. (%)
Clinical course
Relapsing-remitting 38 (72)
Secondary progressive 9 (17)
Primary progressive 4 (8)
Progressive relapsing 2 (4)
Signs and symptoms At onset During the course
Limb weakness 34 (64) 36 (68)
Paraesthesia 35 (66) 36 (68)
Blurring of vision/ 24 (45) 27 (51)
  blindness/scotoma
Vertigo 1 (2) 2 (4)
Dysphasia 1 (2) 1 (2)
Sphincter dysfunction 5 (9) 19 (36)
Ataxia 3 (6) 6 (11)
Facial palsy 1 (2) 2 (4)
Partial transverse myelitis 22 (42) 35 (66)
Cerebellar lesion 12 (23) 13 (25)
EDSS* On diagnosis During last visit
0-3.0 34 (64) 29 (55)
3.5-5.0 11 (21) 9 (17)
5.5-6.0 4 (8) 3 (6)
6.5-7.0 2 (4) 3 (6)
7.5-8.0 2 (4) 8 (15)
8.5-9.0 0 (0) 1 (2)
>9.0 0 (0) 0 (0)
* EDSS Kurtzke’s Expanded Disability Status Scale
Table 3. Investigations in multiple sclerosis
Abnormal Total No.
No. (%)
Evoked potential studies
Visual evoked potential 26 (67) 39
Brainstem auditory evoked potential 11 (32) 34
Somato-sensory evoked potential 18 (62) 29
Cerebrospinal fluid oligoclonal banding 10 (40) 25
Table 4. Use of immunomodulating therapy
Immunomodulating agents Used Currently used
Interferon-beta 13 8
Azathioprine 13 3
Cyclosporin 1 -
Copolymer I 1 -
Intravenous immunoglobulin 1 -
Adrenocorticotrophic hormone 1 -
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abnormalities that were compatible with the diagnosis of
MS. These patients belonged to the clinically definite
diagnostic group that had laboratory-supported evidence.
The remaining seven patients belonged to the clinically
possible diagnostic group, because some investigations,
such as MRI, were not performed. Thirty-five patients had
paraesthesia at the onset of their disease indicating spinal
cord involvement. Nineteen (36%) patients had selective
involvement of their optic nerves and spinal cords. Of
these, four (7.5%) had normal MRI brain scans, and were
included because they satisfied the diagnostic criteria.
The questionnaire revealed that only 25 (47%) of the
53 patients had their CSF sent for oligoclonal banding, a
test that helps confirm the diagnosis of MS. Of these, 10
(40%) had banding present, namely: four (40%) out of 10
patients who presented during a relapsing phase of their
disease; and six (40%) out of 15 patients who presented
during a non-relapsing phase of their disease.
Clinical status
The mean EDSS was 3.0 (range, 0-8.0) at the time of diagno-
sis, increasing to 3.6 (range, 0-8.5) by the last follow-up visit.
In other words, these MS patients, who on average started
with moderate disability were more disabled after 2 years,
although they still remained ambulatory. The mean number
of relapses within the 2-year period (1997-1998) was 1.1.
Discussion
Hong Kong has a population of 6.8 million people, of whom
more than 99.7% are of southern Chinese origin. This study
thus shows that the prevalence of Chinese MS sufferers is
at least 0.77 per 100 000 population. There are 42 hospitals
in Hong Kong, of which 11 are general hospitals receiving
referrals. For complicated diseases, such as MS, patients
will most likely be referred to these hospitals. Hence, we
targeted all the neurologists at these 11 referral hospitals
and followed-up our questionnaires by telephone.
In the event, the neurologists and their hospital notes
provided a comprehensive catchment for all MS patients in
Hong Kong. At the time the survey was conducted (1999),
there were 35 neurologists in Hong Kong. This group
formed a small scientific community characterised by frequent
academic and social meetings. Moreover, they had a track
record of frequent, successful collaborative studies for
diseases, such as epilepsy, stroke, tuberculous meningitis,
and Creuztfeldt-Jacob disease. Added to this, all relevant
records in public hospitals had been computerised and coded
using the International Classification of Disease coding
system. When MS patients were at an advanced stage of
their disease, ie with high EDSS step and much debilitation,
they were cared for by the out-reach medical staff of
public hospitals, the Community Geriatric Ambulatory Team.
It is possible that information from one neurologist who
looked after another two MS patients was overlooked.
When we cross-checked our data with the only MS patient
support group in our locality, the number of participants was
small, and all were under the care of (known) neurologists.
The Chinese MS patient population is a very specific
and highly selected group. Because of its small size, we
tried to identify every individual through stringent diagnostic
criteria, and then only to count those who were being
actively followed-up, as this would provide maximum
patient information. Those MS sufferers who did not attend
any follow-up, or who were being followed-up under the
care of private practitioners, would thus have been beyond
the reach of our survey. However, we believed this number to
be very small, as the treatment provided by public hospitals
was relatively inexpensive and also of a high standard.
A study reported by Yu et al8 in 1989 found that
the prevalence of MS in Hong Kong Chinese was 0.88 per
100 000 population. Hence, the local prevalence of MS in
Chinese appears to have remained persistently low over
the intervening 10-year period. Our study also showed a
high female to male ratio of MS sufferers (9.6:1). In 1999,
the female to male ratio among the general population
of Hong Kong was 49.7:50.3. This combination of a low
prevalence of MS and a high female to male ratio has also
been observed in several other South-East Asian cities/
countries (Table 5).5,8-12  In each case, the female to male
ratio is much higher than in western MS, where it is about
1.5:1. We thus conclude that low prevalence and high
female to male ratio are two characteristics of MS in Asians.
The prevalence of MS in the West varies from 5-25/100 000
in Italy to 59-103/100 000 in Sardinia.13 Comparatively,
Asian MS has a much lower prevalence.
Notably, less than half of the patients had their CSF sent
for oligoclonal banding, which was present in 40%, regard-
less of whether they were in a relapsing or non-relapsing
phase of their disease. This figure is much lower than that
reported for western MS, in which about 80% to 90% of
patients show positive banding. However, positive banding
in the CSF is not a pathognomonic feature for MS, and now-
adays many patients will be investigated with MRI instead
of a lumbar puncture.
Most (72%) patients in this study had relapse-remitting–
type MS, of whom a further majority (71%) had EDSS steps
between 0 and 5.0, meaning that they remained ambulatory.
Caucasian MS patients with these disease characteristics
Table 5. Demographic characteristics of multiple sclerosis in
Asia
City/country Prevalence Female:male
(per 100 000 population)
Hong Kong 0.77*-0.888 9.6:1*
Malaysia9 2 6.6:1
Thailand10 2 4:1
Japan11 4 2.1:15
Taiwan12 0.8 3.2:1
* Data from this study
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are generally expected to benefit from receiving immuno-
modulating therapy. Whether this is also true for their
Chinese counterparts depends, of course, on the degree of
similarity between the two disease types.
Conclusions
This study has shown that the prevalence of MS in Hong
Kong Chinese was at least 0.77 per 100 000 population.
Taken together with the observed high female to male
ratio of sufferers and low CSF oligoclonal banding pres-
ence compared to that observed in western MS, these
findings may imply heterogeneity in the immunogenetic
background of the disease. Accordingly, the response of
Chinese MS patients to interferon treatment will be import-
ant to note.5 Given the small number of patients identified,
a randomised, placebo-controlled trial to test the efficacy
of interferon among Chinese MS sufferers in Hong Kong is
not feasible.14 Collaboration with other areas and countries
is necessary.
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